Altimmune, Inc. (ALT)Healthcare | Biotechnology | Gaithersburg, United States | NasdaqGM
2.99 USD
-0.06
(-1.967%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 2.97 -0.02 (-0.020%) ⇩ (July 13, 2026, 7:56 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:49 a.m. EDT
The long-term investment case is severely compromised by deteriorating fundamentals and a catastrophic multi-year price trajectory. The company is burning cash aggressively, with operating margins in the thousands of percent negative and free cash flow draining reserves. The price history confirms this structural decline, showing a nearly 95% drop over the last eight years, including five consecutive years of negative annual returns. Despite a massive analyst target price suggesting potential for a 400%+ rebound, the underlying business lacks the revenue growth, profitability, or balance sheet strength to justify such optimism without a miraculous turnaround. The short-term outlook remains muted; while the stock is up slightly off its lows, the heavy put options flow and weak statistical forecast signals suggest continued distribution pressure. This is a speculative biotech play with high risk of permanent capital loss, not a viable investment vehicle. |
| Model | MAE |
|---|---|
| MSTL_115 ✓ | 0.099078 |
| AutoTheta | 0.109097 |
| MSTL | 0.118987 |
| AutoARIMA | 0.121942 |
| AutoETS | 0.122116 |
Forecast horizon: 60 days | Selected: MSTL_115
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 0.34 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.346 |
| Excess Kurtosis | -0.77 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2017-01-19 |
| Debt to Equity Ratio | 12.623 |
| Market Cap | 581,477,760 |
| Forward P/E | -3.48 |
| Beta | 0.24 |
| Website | https://altimmune.com |
As of July 11, 2026, 4:49 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest dominates across nearly all expirations, with significant concentration in strikes below the current price (e.g., 1.5, 2.0, 2.5). While there is some call volume at the 3.5 strike, the heavy put positioning suggests a 'bet against' strategy or hedging by existing holders, indicating skepticism about immediate price recovery despite the low implied volatility environment.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.28403753 |
| Address1 | 910 Clopper Road |
| Address2 | Suite 201S |
| All Time High | 137.7 |
| All Time Low | 1.51 |
| Ask | 3.75 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Daily Volume10 Day | 5,546,640 |
| Average Daily Volume3 Month | 4,407,416 |
| Average Volume | 4,407,416 |
| Average Volume10Days | 5,546,640 |
| Beta | 0.241 |
| Bid | 2.16 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 2.181 |
| City | Gaithersburg |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.99 |
| Current Ratio | 29.557 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.02 |
| Day Low | 2.92 |
| Debt To Equity | 12.623 |
| Display Name | Altimmune |
| Dividend Date | 1,536,883,200 |
| Earnings Call Timestamp End | 1,778,675,400 |
| Earnings Call Timestamp Start | 1,778,675,400 |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,786,451,400 |
| Earnings Timestamp Start | 1,786,451,400 |
| Ebitda | -96,103,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.974 |
| Enterprise To Revenue | 7,938.464 |
| Enterprise Value | 285,784,736 |
| Eps Current Year | -0.70857 |
| Eps Forward | -0.85857 |
| Eps Trailing Twelve Months | -0.92 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,484,870,400 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.9012 |
| Fifty Day Average Change | 0.08879995 |
| Fifty Day Average Change Percent | 0.030608008 |
| Fifty Two Week Change Percent | -28.403753 |
| Fifty Two Week High | 6.44 |
| Fifty Two Week High Change | -3.45 |
| Fifty Two Week High Change Percent | -0.53571427 |
| Fifty Two Week Low | 2.56 |
| Fifty Two Week Low Change | 0.43000007 |
| Fifty Two Week Low Change Percent | 0.16796878 |
| Fifty Two Week Range | 2.56 - 6.44 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,495,805,400,000 |
| Float Shares | 164,198,418 |
| Forward Eps | -0.85857 |
| Forward P E | -3.4825351 |
| Free Cashflow | -42,502,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 57 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -66,052,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0040700003 |
| Held Percent Institutions | 0.58068 |
| Implied Shares Outstanding | 194,474,154 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.pharmathene.com/phoenix.zhtml?c=191999&p=irol-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,536,883,200 |
| Last Split Factor | 1:30 |
| Long Business Summary | Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. |
| Long Name | Altimmune, Inc. |
| Market | us_market |
| Market Cap | 581,477,760 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_4866807 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -91,081,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 591,201,428 |
| Number Of Analyst Opinions | 10 |
| Open | 3.01 |
| Operating Cashflow | -71,637,000 |
| Operating Margins | -2,672.4722 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Peg Ratio | 32.62 |
| Phone | 240 654 1450 |
| Post Market Change | -0.01999998 |
| Post Market Change Percent | -0.66889566 |
| Post Market Price | 2.97 |
| Post Market Time | 1,783,986,990 |
| Previous Close | 3.05 |
| Price Eps Current Year | -4.2197666 |
| Price Hint | 4 |
| Price To Book | 1.3709308 |
| Price To Sales Trailing12 Months | 16,152.16 |
| Profit Margins | 0.0 |
| Quick Ratio | 29.427 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0599999 |
| Regular Market Change Percent | -1.96721 |
| Regular Market Day High | 3.02 |
| Regular Market Day Low | 2.92 |
| Regular Market Day Range | 2.92 - 3.02 |
| Regular Market Open | 3.01 |
| Regular Market Previous Close | 3.05 |
| Regular Market Price | 2.99 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 2,446,525 |
| Return On Assets | -0.24399 |
| Return On Equity | -0.42745999 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 194,474,154 |
| Shares Percent Shares Out | 0.2449 |
| Shares Short | 47,634,141 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 39,121,187 |
| Short Name | Altimmune, Inc. |
| Short Percent Of Float | 0.24520001 |
| Short Ratio | 10.92 |
| Source Interval | 15 |
| State | MD |
| Symbol | ALT |
| Target High Price | 28.0 |
| Target Low Price | 2.5 |
| Target Mean Price | 15.45 |
| Target Median Price | 15.5 |
| Total Cash | 331,540,000 |
| Total Cash Per Share | 1.705 |
| Total Debt | 35,847,000 |
| Total Revenue | 36,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.92 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.840325 |
| Two Hundred Day Average Change | -0.8503251 |
| Two Hundred Day Average Change Percent | -0.22142008 |
| Type Disp | Equity |
| Volume | 2,446,525 |
| Website | https://altimmune.com |
| Zip | 20,878 |